Immunotherapy of autoimmunity and cancer: the penalty for success
暂无分享,去创建一个
[1] S. Miller,et al. Antigen-specific tolerance strategies for the prevention and treatment of autoimmune disease , 2007, Nature Reviews Immunology.
[2] E. Small,et al. A Pilot Trial of CTLA-4 Blockade with Human Anti-CTLA-4 in Patients with Hormone-Refractory Prostate Cancer , 2007, Clinical Cancer Research.
[3] C. Robert,et al. What is the role of cytotoxic T lymphocyte-associated antigen 4 blockade in patients with metastatic melanoma? , 2009, The oncologist.
[4] Nitin J. Karandikar,et al. The mechanism of action of glatiramer acetate treatment in multiple sclerosis , 2010, Neurology.
[5] M. Raffeld,et al. Cancer Regression and Autoimmunity in Patients After Clonal Repopulation with Antitumor Lymphocytes , 2002, Science.
[6] Nicki Panoskaltsis,et al. Cytokine storm in a phase 1 trial of the anti-CD28 monoclonal antibody TGN1412. , 2006, The New England journal of medicine.
[7] A. Marmont. Will hematopoietic stem cell transplantation cure human autoimmune diseases? , 2008, Journal of autoimmunity.
[8] D. Arnold,et al. B-cell depletion with rituximab in relapsing-remitting multiple sclerosis. , 2008, The New England journal of medicine.
[9] M. Feldmann,et al. Development of anti-TNF therapy for rheumatoid arthritis , 2002, Nature Reviews Immunology.
[10] M. Freedman,et al. Efficacy of Disease-Modifying Therapies in Relapsing Remitting Multiple Sclerosis: A Systematic Comparison , 2008, European Neurology.
[11] R. Good. Relations between immunity and malignancy. , 1972, Proceedings of the National Academy of Sciences of the United States of America.
[12] D. Gjertson,et al. TNFα blockade in human diseases : An overview of efficacy and safety , 2008 .
[13] S. Rosenberg,et al. Tumor Regression and Autoimmunity in Patients Treated With Cytotoxic T Lymphocyte–Associated Antigen 4 Blockade and Interleukin 2: A Phase I/II Study , 2005, Annals of Surgical Oncology.
[14] O. Finn,et al. Cancer vaccines: a promising cancer therapy against all odds. , 2007, Future oncology.
[15] A. Evans,et al. Induction of a non-encephalitogenic type 2 T helper-cell autoimmune response in multiple sclerosis after administration of an altered peptide ligand in a placebo-controlled, randomized phase II trial , 2000, Nature Medicine.
[16] M. Mochizuki,et al. Cellular autoimmunity to retinal specific antigens in patients with Behçet's disease. , 1993, The British journal of ophthalmology.
[17] A. Feldman,et al. Enterocolitis in patients with cancer after antibody blockade of cytotoxic T-lymphocyte-associated antigen 4. , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[18] T. Waldmann. Anti-Tac (daclizumab, Zenapax) in the Treatment of Leukemia, Autoimmune Diseases, and in the Prevention of Allograft Rejection: A 25-Year Personal Odyssey , 2007, Journal of Clinical Immunology.
[19] G. Adams,et al. Monoclonal antibody therapy of cancer , 1999, Nature Biotechnology.
[20] M. Amagai. Autoimmunity against desmosomal cadherins in pemphigus. , 1999, Journal of dermatological science.
[21] F. Vincenti. Costimulation blockade in autoimmunity and transplantation. , 2008, The Journal of allergy and clinical immunology.
[22] H. Niitani,et al. [Phase II study]. , 1995, Gan to kagaku ryoho. Cancer & chemotherapy.
[23] S. Rosenberg,et al. Cytotoxic T lymphocyte-associated antigen 4 blockade in patients with metastatic melanoma: a new cause of uveitis. , 2004, Journal of immunotherapy.
[24] L. Adorini. Cytokine‐based immunointervention in the treatment of autoimmune diseases , 2003, Clinical and experimental immunology.
[25] S. Verma,et al. Matters of the heart: cardiac toxicity of adjuvant systemic therapy for early-stage breast cancer , 2008, Current oncology.
[26] J. Frank,et al. Encephalitogenic potential of the myelin basic protein peptide (amino acids 83–99) in multiple sclerosis: Results of a phase II clinical trial with an altered peptide ligand , 2000, Nature Medicine.
[27] S. Rosenberg,et al. Adoptive cell transfer therapy following non-myeloablative but lymphodepleting chemotherapy for the treatment of patients with refractory metastatic melanoma. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[28] M. Mochizuki,et al. Ocular infiltrating CD4+ T cells from patients with Vogt-Koyanagi-Harada disease recognize human melanocyte antigens. , 2006, Investigative ophthalmology & visual science.
[29] J. Lindstrom. Acetylcholine receptors and myasthenia , 2000, Muscle & nerve.
[30] T. Nomura,et al. Regulatory T Cells and Immune Tolerance , 2008, Cell.
[31] J. Browning. B cells move to centre stage: novel opportunities for autoimmune disease treatment , 2006, Nature Reviews Drug Discovery.
[32] D. Harlan,et al. A Single Course of Anti-CD3 Monoclonal Antibody hOKT3γ1(Ala-Ala) Results in Improvement in C-Peptide Responses and Clinical Parameters for at Least 2 Years after Onset of Type 1 Diabetes , 2005, Diabetes.
[33] J. Bluestone,et al. CD3-specific antibodies: a portal to the treatment of autoimmunity , 2007, Nature Reviews Immunology.
[34] Carmen Birchmeier,et al. Conditional mutation of the ErbB2 (HER2) receptor in cardiomyocytes leads to dilated cardiomyopathy , 2002, Proceedings of the National Academy of Sciences of the United States of America.
[35] C. Rooney,et al. Improving T cell therapy for cancer. , 2007, Expert opinion on biological therapy.
[36] M. Debandt. Lessons for lupus from tumour necrosis factor blockade , 2006 .
[37] S. Rosenberg,et al. Adoptive cell transfer: a clinical path to effective cancer immunotherapy , 2008, Nature Reviews Cancer.
[38] J. Passweg,et al. Autologous stem cell transplantation in autoimmune diseases. , 2007, Seminars in hematology.
[39] K. Norose,et al. Melanoma specific Th1 cytotoxic T lymphocyte lines in Vogt-Koyanagi-Harada disease. , 1996, The British journal of ophthalmology.
[40] J. Rose,et al. Monoclonal antibody treatments for multiple sclerosis , 2008, Current neurology and neuroscience reports.
[41] L. Chatenoud. Immune therapies of autoimmune diseases: are we approaching a real cure? , 2006, Current opinion in immunology.
[42] D. Paty,et al. TNF neutralization in MS , 1999, Neurology.
[43] E. Zerhouni,et al. The Biomarkers Consortium: public and private sectors working in partnership to improve the public health. , 2007, The Oncologist.
[44] George Kollias,et al. Uncoupling the Proinflammatory from the Immunosuppressive Properties of Tumor Necrosis Factor (Tnf) at the P55 TNF Receptor Level , 2001, The Journal of experimental medicine.
[45] E. Arbustini,et al. Immunosuppression and cancer: A comparison of risks in recipients of organ transplants and in HIV-positive individuals. , 2006, Transplantation proceedings.
[46] V. Singh,et al. Human S-antigen: peptide determinant recognition in uveitis patients. , 2004, Experimental and molecular pathology.
[47] T. Waldmann,et al. Treatment of noninfectious intermediate and posterior uveitis with the humanized anti-Tac mAb: a phase I/II clinical trial. , 1999, Proceedings of the National Academy of Sciences of the United States of America.
[48] S. Rosenberg,et al. Autoimmunity correlates with tumor regression in patients with metastatic melanoma treated with anti-cytotoxic T-lymphocyte antigen-4. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[49] P. Lipsky,et al. Infliximab in active early rheumatoid arthritis , 2004, Annals of the rheumatic diseases.
[50] C. Scott. The problem with potency , 2005, Nature Biotechnology.
[51] L. Steinman,et al. Design of effective immunotherapy for human autoimmunity , 2005, Nature.
[52] D. Neuberg,et al. Immunologic and clinical effects of antibody blockade of cytotoxic T lymphocyte-associated antigen 4 in previously vaccinated cancer patients , 2008, Proceedings of the National Academy of Sciences.
[53] B. Roep. T-Cell Responses to Autoantigens in IDDM: The Search for the Holy Grail , 1996, Diabetes.
[54] J. Schlom,et al. Preclinical and clinical studies of recombinant poxvirus vaccines for carcinoma therapy. , 2007, Critical reviews in immunology.
[55] Constant Beckers. The search for the Holy Grail , 2007 .
[56] I. Buchan,et al. Anti-TNF antibody therapy in rheumatoid arthritis and the risk of serious infections and malignancies: systematic review and meta-analysis of rare harmful effects in randomized controlled trials. , 2006, JAMA.
[57] M. Wei,et al. Bacterial targeted tumour therapy-dawn of a new era. , 2008, Cancer letters.
[58] Y. Suzuki,et al. T cell immune responses against melanoma and melanocytes in cancer and autoimmunity. , 2000, Pigment cell research.
[59] G. Parmiani,et al. Cytokines in cancer therapy. , 2000, Immunology letters.